RE:RE:RE:RE:RE:RE:RE:RE:Intercept slips due SAFETY of Ocaliva That's why I have been repeating myself many times re marketing the R&D programs,if the company can increase the sales using different strategies it's great failing that both protocols require funds sooner or later so the company either bite the bullet and issue an offering before the SP moves higher or possibly a partnership agreement.
If they manage to close the valuation gap between THTX and compatible NASH companies by aggressively marketing their programs NOW the upcoming dilution won't be as painful vs an offering based on current depressed SP.
Also if they manage to establish THTX as a phase 3 NASH company I am sure they will be in a more favourable position finding a suitable partner thus no need for share offering.
palinc2000 wrote: The delay in releasing the Q3 financials coupled with the pre announcement of the bad sales results indicate that the odds of submitting the NDA are high imo,The CC will be about the future and not on the sub par results but at the same time I hope they adress the sales trajectory for the coming quarters .....
We need soon 20 million in Quaeterly sales trending towars 25 million by 3 rd Quarter 2021
SPCEO1 wrote: Based on what the company has said on this subject, sometime this week would be likely. The fact that they chose to release their Q3 financials later than normal tells me they are likely trying to have the protocol submitted by10/15 so they can announce that at the same time. But, these things are pretty complicated so don't be surprised if we have to wait a bit longer than 10/15.
ggg088 wrote: Who can estimate the time of the submission to FDA?